Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomatrix (BXM) Looking Great -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (307)	1/1/1998 2:21:00 PM
From: John McCarthy	Read Replies (1) \| Respond to of 569

Hylaform to miss 1998 - dljdirect.com Regards, John

To: John McCarthy who wrote (307)	1/1/1998 10:17:00 PM
From: tnsaf	Read Replies (1) \| Respond to of 569

<<In early 1997 the FDA became aware of this, and in the course of 5 weeks - FROM A STANDING STOP - BMY filed with the FDA to have TAXOL reviewed under the Orphan Drug Statutes AND the FDA agreed to review their request. This was in June. In August the FDA ruled that TAXOL ($1 bil. drug) was indeed an ORPHAN DRUG.>> I thought drugs were orphaned for specific indications, such as Taxol for KS but not ovarian cancer. Jason